Streetbeat News

LRMR

Larimar Therapeutics, Inc.

https://www.larimartx.com

Industry

Biotechnology

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Open

2.52

Mkt cap

160M

Volume

473K

High

2.60

P/E Ratio

-2.18

52-wk high

11.20

Low

2.50

Div yield

N/A

52-wk low

2.29

Wedbush analyst Laura Chico has initiated coverage on Larimar Therapeutics (NASDAQ:LRMR) with an Outperform rating and set a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 1:49 pm

HC Wainwright & Co. has initiated coverage on Larimar Therapeutics with a Buy rating and set a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 10:12 am

Larimar Therapeutics shares rose following the announcement that data from its Nomlabofusp Phase 1 and Phase 2 studies will be presented at the International Congress for Ataxia Research.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 3:43 pm

Larimar Therapeutics will present data from its Nomlabofusp Phase 1 and Phase 2 studies at the Annual International Congress for Ataxia Research. Some of this data has been previously disclosed.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 11:29 am

Jones Trading has initiated coverage on Larimar Therapeutics with a Buy rating and set a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:06 pm

G-III Apparel Group's shares surged 23.6% after reporting better-than-expected Q2 EPS and issuing strong FY25 guidance. Other stocks like Applied Digital, Yext, and NIO also saw significant gains due to positive financial results and strategic developments.

Portfolio Pulse from Avi Kapoor

September 05, 2024 | 5:44 pm

Baird has initiated coverage on Larimar Therapeutics with an Outperform rating and set a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 9:42 am

Larimar Therapeutics reported a Q2 2024 GAAP EPS of $(0.34), missing the $(0.32) estimate. As of June 30, 2024, the company had $226.1M in cash, cash equivalents, and marketable securities, providing a projected cash runway into 2026.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:16 am

Worthington Enterprises, Taysha Gene Therapies, General Mills, and other major stocks are experiencing declines in Wednesday's pre-market session. Worthington Enterprises missed earnings and revenue estimates, leading to a 7.5% drop. Taysha Gene Therapies fell 14% due to a proposed public offering. General Mills slipped 4.5% following its fourth-quarter results.

Portfolio Pulse from Avi Kapoor

June 26, 2024 | 11:36 am

Several major stocks, including AMC Networks, Louisiana-Pacific, and others, are experiencing declines in Monday's pre-market session. AMC Networks fell sharply due to a private offering of convertible senior notes, while Louisiana-Pacific was downgraded by Goldman Sachs.

Portfolio Pulse from Avi Kapoor

June 17, 2024 | 11:41 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.